Drugs Looking for Diseases: Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists
We all know how much time, effort and money it takes to develop a new drug. Hundreds of chemical compounds have to be synthesized and thousands of different activities in biology, physiology, pharmacology, clinical investigation, management and marketing have to be initiated and coordinated. Each ne...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Dordrecht
Springer Netherlands
1991
|
| Schriftenreihe: | Developments in Cardiovascular Medicine
120 |
| Schlagworte: | |
| Online-Zugang: | UBR01 URL des Erstveröffentlichers |
| Zusammenfassung: | We all know how much time, effort and money it takes to develop a new drug. Hundreds of chemical compounds have to be synthesized and thousands of different activities in biology, physiology, pharmacology, clinical investigation, management and marketing have to be initiated and coordinated. Each new drug starts a voyage of discovery through an unmapped terrain which is shrouded in mist and beset by pitfalls, as Dr. Rein Vos puts it in his absorbing inside story of the development of the beta-adrenoceptor blocking agents and the calcium antagonists. Indeed we know, for example, how long it took before the theory of Ahlquist of the alpha and beta adrenergic receptors was widely accepted. Similarly, it suffices to memorize shortly the difficulty of expanding the new concept of calcium antagonism through the national German boundaries into the world. This shows how laborious and complex pharmaceutical progress is, and we all will benefit from a deeper understanding of the process of innovative drug research |
| Beschreibung: | 1 Online-Ressource (XXX, 381 p) |
| ISBN: | 9789401137966 |
| DOI: | 10.1007/978-94-011-3796-6 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046144980 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1991 |||| o||u| ||||||eng d | ||
| 020 | |a 9789401137966 |9 978-94-011-3796-6 | ||
| 024 | 7 | |a 10.1007/978-94-011-3796-6 |2 doi | |
| 035 | |a (ZDB-2-SME)978-94-011-3796-6 | ||
| 035 | |a (OCoLC)1119015901 | ||
| 035 | |a (DE-599)BVBBV046144980 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.12 |2 23 | |
| 084 | |a XI 4400 |0 (DE-625)153006:12905 |2 rvk | ||
| 100 | 1 | |a Vos, Rein |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Drugs Looking for Diseases |b Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists |c by Rein Vos |
| 264 | 1 | |a Dordrecht |b Springer Netherlands |c 1991 | |
| 300 | |a 1 Online-Ressource (XXX, 381 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Developments in Cardiovascular Medicine |v 120 | |
| 520 | |a We all know how much time, effort and money it takes to develop a new drug. Hundreds of chemical compounds have to be synthesized and thousands of different activities in biology, physiology, pharmacology, clinical investigation, management and marketing have to be initiated and coordinated. Each new drug starts a voyage of discovery through an unmapped terrain which is shrouded in mist and beset by pitfalls, as Dr. Rein Vos puts it in his absorbing inside story of the development of the beta-adrenoceptor blocking agents and the calcium antagonists. Indeed we know, for example, how long it took before the theory of Ahlquist of the alpha and beta adrenergic receptors was widely accepted. Similarly, it suffices to memorize shortly the difficulty of expanding the new concept of calcium antagonism through the national German boundaries into the world. This shows how laborious and complex pharmaceutical progress is, and we all will benefit from a deeper understanding of the process of innovative drug research | ||
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Philosophy of Medicine | |
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Medicine-Philosophy | |
| 650 | 0 | 7 | |a Calciumantagonist |0 (DE-588)4069807-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Beta-Blocker |0 (DE-588)4006088-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Geschichte |0 (DE-588)4020517-4 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Beta-Blocker |0 (DE-588)4006088-3 |D s |
| 689 | 0 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | 2 | |a Geschichte |0 (DE-588)4020517-4 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 689 | 1 | 0 | |a Calciumantagonist |0 (DE-588)4069807-5 |D s |
| 689 | 1 | 1 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 1 | 2 | |a Geschichte |0 (DE-588)4020517-4 |D s |
| 689 | 1 | |8 2\p |5 DE-604 | |
| 689 | 2 | 0 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |D s |
| 689 | 2 | 1 | |a Calciumantagonist |0 (DE-588)4069807-5 |D s |
| 689 | 2 | |8 3\p |5 DE-604 | |
| 689 | 3 | 0 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |D s |
| 689 | 3 | 1 | |a Beta-Blocker |0 (DE-588)4006088-3 |D s |
| 689 | 3 | |8 4\p |5 DE-604 | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792309680 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401056892 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9789401137973 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-94-011-3796-6 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525165 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 4\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-94-011-3796-6 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180481059586048 |
|---|---|
| any_adam_object | |
| author | Vos, Rein |
| author_facet | Vos, Rein |
| author_role | aut |
| author_sort | Vos, Rein |
| author_variant | r v rv |
| building | Verbundindex |
| bvnumber | BV046144980 |
| classification_rvk | XI 4400 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-94-011-3796-6 (OCoLC)1119015901 (DE-599)BVBBV046144980 |
| dewey-full | 616.12 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12 |
| dewey-search | 616.12 |
| dewey-sort | 3616.12 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-94-011-3796-6 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04041nmm a2200733zcb4500</leader><controlfield tag="001">BV046144980</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1991 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789401137966</subfield><subfield code="9">978-94-011-3796-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-94-011-3796-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-94-011-3796-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119015901</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046144980</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4400</subfield><subfield code="0">(DE-625)153006:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vos, Rein</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drugs Looking for Diseases</subfield><subfield code="b">Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists</subfield><subfield code="c">by Rein Vos</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Dordrecht</subfield><subfield code="b">Springer Netherlands</subfield><subfield code="c">1991</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XXX, 381 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Developments in Cardiovascular Medicine</subfield><subfield code="v">120</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We all know how much time, effort and money it takes to develop a new drug. Hundreds of chemical compounds have to be synthesized and thousands of different activities in biology, physiology, pharmacology, clinical investigation, management and marketing have to be initiated and coordinated. Each new drug starts a voyage of discovery through an unmapped terrain which is shrouded in mist and beset by pitfalls, as Dr. Rein Vos puts it in his absorbing inside story of the development of the beta-adrenoceptor blocking agents and the calcium antagonists. Indeed we know, for example, how long it took before the theory of Ahlquist of the alpha and beta adrenergic receptors was widely accepted. Similarly, it suffices to memorize shortly the difficulty of expanding the new concept of calcium antagonism through the national German boundaries into the world. This shows how laborious and complex pharmaceutical progress is, and we all will benefit from a deeper understanding of the process of innovative drug research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Philosophy of Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine-Philosophy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Beta-Blocker</subfield><subfield code="0">(DE-588)4006088-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Geschichte</subfield><subfield code="0">(DE-588)4020517-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Beta-Blocker</subfield><subfield code="0">(DE-588)4006088-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Geschichte</subfield><subfield code="0">(DE-588)4020517-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Geschichte</subfield><subfield code="0">(DE-588)4020517-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Calciumantagonist</subfield><subfield code="0">(DE-588)4069807-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2="1"><subfield code="a">Beta-Blocker</subfield><subfield code="0">(DE-588)4006088-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="8">4\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792309680</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401056892</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9789401137973</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-94-011-3796-6</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525165</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">4\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-94-011-3796-6</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046144980 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:26Z |
| institution | BVB |
| isbn | 9789401137966 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525165 |
| oclc_num | 1119015901 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XXX, 381 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1991 |
| publishDateSearch | 1991 |
| publishDateSort | 1991 |
| publisher | Springer Netherlands |
| record_format | marc |
| series2 | Developments in Cardiovascular Medicine |
| spelling | Vos, Rein Verfasser aut Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists by Rein Vos Dordrecht Springer Netherlands 1991 1 Online-Ressource (XXX, 381 p) txt rdacontent c rdamedia cr rdacarrier Developments in Cardiovascular Medicine 120 We all know how much time, effort and money it takes to develop a new drug. Hundreds of chemical compounds have to be synthesized and thousands of different activities in biology, physiology, pharmacology, clinical investigation, management and marketing have to be initiated and coordinated. Each new drug starts a voyage of discovery through an unmapped terrain which is shrouded in mist and beset by pitfalls, as Dr. Rein Vos puts it in his absorbing inside story of the development of the beta-adrenoceptor blocking agents and the calcium antagonists. Indeed we know, for example, how long it took before the theory of Ahlquist of the alpha and beta adrenergic receptors was widely accepted. Similarly, it suffices to memorize shortly the difficulty of expanding the new concept of calcium antagonism through the national German boundaries into the world. This shows how laborious and complex pharmaceutical progress is, and we all will benefit from a deeper understanding of the process of innovative drug research Cardiology Philosophy of Medicine Medicine-Philosophy Calciumantagonist (DE-588)4069807-5 gnd rswk-swf Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Beta-Blocker (DE-588)4006088-3 gnd rswk-swf Arzneimittelforschung (DE-588)4003120-2 gnd rswk-swf Geschichte (DE-588)4020517-4 gnd rswk-swf Beta-Blocker (DE-588)4006088-3 s Arzneimittelentwicklung (DE-588)4143176-5 s Geschichte (DE-588)4020517-4 s 1\p DE-604 Calciumantagonist (DE-588)4069807-5 s 2\p DE-604 Arzneimittelforschung (DE-588)4003120-2 s 3\p DE-604 4\p DE-604 Erscheint auch als Druck-Ausgabe 9780792309680 Erscheint auch als Druck-Ausgabe 9789401056892 Erscheint auch als Druck-Ausgabe 9789401137973 https://doi.org/10.1007/978-94-011-3796-6 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 4\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Vos, Rein Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists Cardiology Philosophy of Medicine Medicine-Philosophy Calciumantagonist (DE-588)4069807-5 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Beta-Blocker (DE-588)4006088-3 gnd Arzneimittelforschung (DE-588)4003120-2 gnd Geschichte (DE-588)4020517-4 gnd |
| subject_GND | (DE-588)4069807-5 (DE-588)4143176-5 (DE-588)4006088-3 (DE-588)4003120-2 (DE-588)4020517-4 |
| title | Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists |
| title_auth | Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists |
| title_exact_search | Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists |
| title_full | Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists by Rein Vos |
| title_fullStr | Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists by Rein Vos |
| title_full_unstemmed | Drugs Looking for Diseases Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists by Rein Vos |
| title_short | Drugs Looking for Diseases |
| title_sort | drugs looking for diseases innovative drug research and the development of the beta blockers and the calcium antagonists |
| title_sub | Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists |
| topic | Cardiology Philosophy of Medicine Medicine-Philosophy Calciumantagonist (DE-588)4069807-5 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Beta-Blocker (DE-588)4006088-3 gnd Arzneimittelforschung (DE-588)4003120-2 gnd Geschichte (DE-588)4020517-4 gnd |
| topic_facet | Cardiology Philosophy of Medicine Medicine-Philosophy Calciumantagonist Arzneimittelentwicklung Beta-Blocker Arzneimittelforschung Geschichte |
| url | https://doi.org/10.1007/978-94-011-3796-6 |
| work_keys_str_mv | AT vosrein drugslookingfordiseasesinnovativedrugresearchandthedevelopmentofthebetablockersandthecalciumantagonists |